Posted by Michael Wonder on 01 Jul 2016
AbbVie's Humira (adalimumab) receives U.S. FDA approval to treat adults with non-infectious intermediate, posterior and panuveitis
30 June 2016 - Approval marks the 10th approved indication for Humira in the United States and follows recent European Commission marketing authorization for this indication.
AbbVie today announced that the U.S. FDA has approved Humira (adalimumab) for the treatment of non-infectious intermediate, posterior and panuveitis. Humira is now the first and only FDA-approved non-corticosteroid therapy available for adults with non-infectious intermediate, posterior and panuveitis. This approval marks the 10th approved indication for Humira in the United States for immune-mediated diseases.
This month, the European Commission also approved Humira in the European Union for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate.
